Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Five ways to make the most of your streamlined sales force

Maureen Shaffer returns with tips on optimising your sales force. 50,000 jobs were cut by pharma in 2010, and in July 2011, “Thanks to Merck, pharma's July job cuts outpaced layoffs announced in every...

Articles

Editor’s voice – August 2011: Happy Birthday pharmaphorum!

As pharmaphorum reaches the grand old age of two Paul Tunnah and Rebecca Aris mix the usual upcoming content highlights with some rather special awards looking back. Happy Birthday to us! Today is officially pharmaphorum’s second birthday, as precisely 2 years ago on this very day the website went live and...

Articles

Rare is different: how empowered patients and caregivers are...

In our new series ‘Rare is different’ we hear from caregivers of patients with rare diseases to see what advice they offer to marketers and to remind us of the point of it all – the patient! In a six-part series titled "Rare is different," we’ll show you how the world of rare diseases is unlike other pharma markets, particularly in the...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.